Entity

Time filter

Source Type

Burlington, NC, United States

Adcock D.M.,Laboratory Corporation of America Holdings | Gosselin R.,University of California at Davis
Thrombosis Research | Year: 2015

Direct oral anticoagulant therapies, including direct anti-Xa and thrombin inhibitors have recently been introduced and may have advantages over vitamin K antagonists such as warfarin. This review describes briefly the clinical utility and mechanism of action of these agents. Detailed information is provided on effect of these agents on routine assays including the APTT and PT as well as their impact on specialty laboratory assays. Also included are the use of drug specific assays and a discussion of alternative methods to determine relative drug concentration, such as evaluating drug calibrators in APTT and PT assays and using heparin calibrated anti-Xa assays to measure direct Xa inhibitors. © 2015 The Authors.


Patent
Laboratory Corporation of America Holdings | Date: 2014-02-19

The invention relates to methods for indirectly determining clinical laboratory reference intervals. In one aspect, a reference interval is determined using all measurements for a given analyte stored in a large existing database. In other aspects, a characteristic of a subject is used to select a reference population for inclusion in reference interval calculations. In other aspects, the invention provides methods for changing treatment plan, diagnosis, or prognosis for an individual subject based on differences between the new reference interval and a previously utilized reference interval. In other aspects, the invention provides systems and computer readable media for indirectly determining reference intervals.


Patent
Laboratory Corporation of America Holdings | Date: 2015-07-17

The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.


Patent
International Aids Vaccine Initiative and Laboratory Corporation Of America Holdings | Date: 2014-09-05

The present application relates to identifying one or more components of HIV envelope glycoprotein which bind to broadly neutralizing antibodies, which may be utilized as research tools for developing HIV-1 vaccine immunogens, antigens for crystallization and/or for identifying of broad neutralizing antibodies.


Systems and methods are provided for facilitating diagnosis, prognosis and treatment of cancer based on detection of HER3 activation. The systems and methods involve analysis of samples for the presence or the absence of activated HER3 markers as indicated by HER2-HER3 heterodimers, HER3 phosphorylation, or recruitment of PI3K to activated HER3 (HER3/PI3K complexes). The amounts of activated HER3 marker expression may be measured alone or in conjunction with other biomarkers.

Discover hidden collaborations